Immgenuity

Immgenuity is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of HIV patients. The company's lead candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has demonstrated safety in preclinical studies. Immgenuity is led by an experienced team of biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development.